Background: Alzheimer's disease (AD) is growing in frequency and new therapies are urgently needed. Methods: We assessed clinicaltrials.gov (accessed 1-4-2016) to determine the number and characteristics of trials in phase I, phase II, and phase III for treatment of AD. Alzheimer's disease (AD) is rapidly becoming a major public health threat with increasing numbers of affected individuals as the world's population ages. There are currently 5.3 million Americans and 35 million people worldwide with AD dementia, and the number will increase to nearly 15 million in the United States and over 100 million globally by 2050 if treatments are not found [1, 2] .
Alzheimer's disease (AD) is rapidly becoming a major public health threat with increasing numbers of affected individuals as the world's population ages. There are currently 5.3 million Americans and 35 million people worldwide with AD dementia, and the number will increase to nearly 15 million in the United States and over 100 million globally by 2050 if treatments are not found [1, 2] .
New therapies are needed for this burgeoning population of affected and at-risk persons that improve the symptoms of patients with memory and cognitive decline, prevent or delay the onset of AD in individuals who are at-risk for the disease, or slow progression in those with declining cognition. New therapies are being assessed in clinical trials but the success rate of AD drug development has been low with the last new novel agent approved in 2003 [3] .
To gain insight into the current AD treatment pipeline, we reviewed all trials registered in clinicaltrials.gov (accessed 1/4/2016), the US government website that lists all US and most global clinical trials. Registration of new trials on the site is required for trials approved by the US Food and Drug Administration (FDA) since 2007 [4] . We reviewed this comprehensive website for all agents in clinical trials for AD dividing them into those in phase I, phase II, and phase III. The purpose of the study was to understand the landscape of AD drug development and determine evolutions occurring in AD drug development from historical practices. The goal is to assess the state of AD drug development, anticipate the emergence of new therapies, review emerging pharmacologic mechanisms and clinical trial approaches, and derive lessons possibly helpful in the drug development process.
Methods
We interrogated clinicaltrials.gov with the information summarized here accessed on January 4, 2016. We used the search features of the site to capture all agents listed for AD in phase I, II, and III. We captured the trial title, beginning date, anticipated ending date, anticipated duration, number of subjects to be enrolled, number of arms of the study (usually a placebo arm and one or more treatment arms with different doses of the test agent), whether a biomarker was described, and whether the sponsor was a biopharma company, the National Institutes of Health (NIH), a combination of biopharma and NIH, or "other. " We included trials that were recruiting, active but not recruiting-trials that have completed recruiting and are continuing as the efficacy or safety of the agent is being determined-and enrolling by invitation. We did not include trials listed as not yet recruiting, completed, terminated, suspended, or withdrawn. These exclusions were based on our interest in the currently active pipeline and what agents could evolve in the near term. Reasons for terminating, suspending, or withdrawing trials are often not provided, and we could not draw conclusions about these trials or the agents involved. The agents and trials reviewed comprise a comprehensive list of agents currently in trials. The list is not exhaustive because not all non-US trials are registered on clinicaltrials.gov, and there is sometimes a delay in registering trials. The mechanism of action of each agent was determined from the information on clinicaltrials.gov (e.g., the mechanism is often noted in the title of the trial or in a description of the trial) or from a comprehensive search of the literature if the mechanism was not provided on the federal website. In a few cases, the mechanism is undisclosed. We grouped the mechanisms into symptomatic or disease modifying. We further divided the symptomatic agents into those that were putative cognitive-enhancing agents or those that addressed neuropsychiatric symptoms. Disease-modifying therapies (DMT) were divided into those that targeted amyloidrelated targets, those that aimed at modifying tau-related mechanisms and those with "other" mechanisms such as neuroprotection or metabolic effects [5] . The definitions of disease-modification and neuroprotection are controversial and evolving [6, 7] ; the terminology is used here to conveniently classify the types of mechanisms for agents in current AD drug-development programs. We did not include nonpharmacologic therapeutic approaches such as devices, cognitive therapies, and medical foods.
Results
There are currently 93 agents in some phase of drug development for AD. Fig. 1 provides a comprehensive overview of the agents currently in clinical trials for AD.
Phase III
There are 24 agents in 36 trials in phase III of AD drug development. Eight agents are in two or more clinical trials. Of the agents in trials, seven are symptomatic treatments targeting neurotransmitter pathways with cognitive enhancement (3) or neuropsychiatric (4) effects. Encenicline, a nicotinic cognitive-enhancing agent, was put on clinical hold by the FDA pending the review of gastrointestinal effects seen in some trial participants. Of the 17 DMTs in phase III, 12 are small molecules, and 5 are immunotherapies. All the immunotherapies and 8 of the 12 small molecules are directed at amyloid-related targets. There are four beta-site amyloid precursor protein cleaving enzyme (BACE) inhibitors in phase III trials. Amyloid-targeting agents comprise 76% of the late-stage DMT pipeline. There is one antitau agent in phase III-TRx0237.
The mean duration of trials of symptomatic agents was 23.3 weeks; the mean duration of DMT trials was 114.1 weeks. In these phase III trials, the mean number of subjects per arm for symptomatic trials is 392.2 and for trials of DMT agents is 516.1.
Eighty-eight percent (32 of 36) of trials are sponsored by the biopharma industry, 2 are jointly sponsored by NIH and industry, and 2 are sponsored by "other" entities. Table 1 shows the agents in phase III with their mechanism of action.
Phase II
There are 45 agents in phase II of AD drug development being assessed in 52 clinical trials. The pipeline includes 12 symptomatic cognitive-enhancing agents and three agents addressing neuropsychiatric symptoms. There are 30 DMTs being studied in phase II drug development programs; 26 of these are small molecules and four are immunotherapies. Amyloid-related targets comprise the mechanism of action of nine of the 26 small molecules and all four of the immunotherapies. Forty-three percent of phase II DMTs have amyloid-targeting mechanisms of action. Sixteen agents have "other mechanisms" including ten putative neuroprotective agents and six addressing metabolic problems. There is one antitau agent in phase II and one stem cell program (with two trials) in phase II of development.
Phase II trials of symptomatic agents have a mean duration of 19.1 weeks and trials of DMTs in phase II have a mean duration of 49.5 weeks. On average, there are 67.1 subjects per arm in phase II trials of symptomatic treatments and 76.9 subjects per arm in trials of DMT agents.
Of the 52 trials for the 45 agents, 29 are industrysponsored, four are sponsored by NIH, and 18 are sponsored by "other" entities such as academic medical centers and philanthropic foundations. One trial is jointly sponsored by NIH and industry. Table 2 shows the agents in phase II with their mechanism of action.
Phase I
There are 24 agents in phase I AD drug-development programs. Of these, three are symptomatic agents, 13 are small molecule DMTs, and eight are DMT immunotherapies. Five of the 13 small molecules and seven of the eight immunotherapies address amyloid-related mechanisms (57% of the DMT mechanisms). One tau-directed antibody and one tau-related small molecule are included in the AD phase I pipeline. Five neuroprotective agents and two metabolic agents are being assessed.
Of the 27 trials of phase I agents, 20 are sponsored by the biopharma industry, two are funded by NIH, one is jointly supported by NIH and industry, and four are funded through other mechanisms. Table 3 shows the agents in phase I with their mechanism of action.
Biomarkers
Biomarkers are playing an increasingly important role in clinical trials of DMTs. Not all trials on clinicaltrials.gov state if biomarkers are included in their trials or discuss the type of biomarkers included, and we discuss the percent of trials that describe which biomarkers are included (Table 4 ). In current phase III trials, measurement of cerebrospinal fluid (CSF) amyloid beta protein (Ab) is the most commonly used biomarker (27.7% of trials reporting use of biomarkers), followed by volumetric magnetic resonance imaging (MRI; 25%), CSF tau, and amyloid positron emission tomography (PET; 22.2% each), fluorodeoxyglucose (FDG) PET (19.4%), plasma amyloid (8.3%), and tau PET (2.7%). Phase II biomarkers include CSF amyloid (25%), CSF tau (21.2%), volumetric MRI (15.4%), FDG PET (11.5%), amyloid PET (9.6%), plasma amyloid (5.8%), and plasma tau (3.8%). 
Discussion
This analysis of clinicaltrials.gov reveals that there are relatively few agents in AD drug-development programs. The high failure rate in AD drug development and the small number of drugs being assessed suggest that the emergence of a repertoire of AD agents that could be tailored to fit the individual needs of patients is unlikely. The small number of agents in phase I is especially concerning as this phase is the major source of drugs for later stage development. A few repurposed agents can enter at phase II or phase III, but these agents generally have limited patent lives or limited intellectual property opportunities and do not comprise a major source of new candidate compounds [8] . Likewise, immunotherapies often begin in phase I/phase II with patients diagnosed with AD to avoid the risk of permanently altering the immune system of normal volunteers but, as can be seen, there are only a few such agents entering the drugdevelopment pipeline. Overall, the AD ecosystem of AD drug development must be altered to yield more targets and more candidate therapies if a robust pipeline of therapies is to be established.
Other reviews of AD drug development have led to similar conclusions as those presented here. The comprehensive 2010 review by Mangialasche et al. [9] showed that new approaches to cholinergic therapy and many antiamyloid trials were being pursued. There were more agents directed toward tau-related targets in the 2010 pipeline review; most of these have since failed. Fig. 1 is similar to the visualization approach used by Mangialasche et al. [9] and can be used to compare changes over a 6-year period. Similarly, Cummings et al [3] found-using a similar strategy to that used in the current review-that there were relatively few drugs being assessed and that the overall failure rate for AD drug development was a dramatic 99.6%. They also noted that no new novel drugs for AD had been approved since 2003.
We compared AD drug development with oncology drug development to provide a perspective on the observed numbers. In the 2014-2015 period, 135 trials were registered for AD, whereas 4976 trials were registered for cancer (these figures were generated from clinicaltrials.gov using the same search terms as used in the reviewed AD trials and agents). This indicates that the number of agents in trials is much larger for cancer than for AD and the likelihood of finding effective therapies is greater. This disparity likely reflects several influences including the greater success of rate of cancer drug development (19.8% of development programs succeed in cancer vs less than 1 percent of AD drugs [3, 10] ). Thirty-one percent of FDA new drug approvals for 2015 were for oncology agents [11] . The low success rate of AD drug development discourages pharmaceutical companies from pursuing research in this area and reduces the enthusiasm of venture capitalists for investing in biotechnology companies whose products address AD-related targets. As a result, fewer targets are identified, and fewer candidate agents discovered and developed. The biological understanding of Abbreviations: BACE, beta-site amyloid precursor protein cleaving enzyme; PPAR, peroxisome proliferator-activated receptor; RAGE, receptor for advanced glycation end products.
NOTE. Twenty-four agents in 36 phase III clinical trials currently ongoing (active, not recruiting, and active, recruiting) as of January 4, 2016 according to clinicaltrials.gov. *Same trial studying gantenerumab and solanezumab independently. Abbreviations: AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; BACE, beta-site amyloid precursor protein cleaving enzyme. GM-CSF, granulocyte-macrophage colony-stimulating factor; HMG-CoA cancer has identified more putative targets. Greater insight into AD pathophysiology may lead to more target identification and more opportunities to develop mechanistically informed treatments. The AD drug-development pipeline has amyloid betaprotein production or removal as it major focus. Across all phases, 56% of DMTs have an amyloid-related target. Monoclonal antibodies and BACE inhibitors comprise the two most developed pathways in the current pipeline. Monoclonal antibody approaches have instituted two major changes in drug development based on experiences with the failure of bapineuzumab: (1) patient populations with more mild disease are now the focus of trials [12] ; (2) amyloid imaging or CSF Ab measures are performed at baseline to insure that patients have the target pathology for antiamyloid therapies [13, 14] . BACE inhibitors have included measures of CSF Ab to demonstrate target engagement and show that the putative goal of reduction is being achieved [15] . Demonstration of target engagement early in the development process makes it more likely-without proving-that clinical benefits may follow long-term therapy [16] .
Tau is a relatively unexploited target with only four agents in the pipeline devoted to tau-related pathophysiology. The availability of tau imaging and the consistent relationships shown between tau signals on imaging and the clinical state of the individual indicate that tau is an important target for drug development and that tau imaging may serve as a useful biomarker to help guide drug development [17] [18] [19] [20] . Tau protein is being targeted in trials of experimental therapies for tauopathies including frontotemporal dementia and progressive supranuclear palsy, and learnings from these trials may inform treatment of tau pathology in AD.
Thirty-eight percent of DMTs are small molecule agents that address neuroprotection or metabolic targets such as insulin resistance or PPAR-gamma-related mechanisms. These approaches are more well represented in phase II than phase III and suggest that the repertoire of targets is broadening for agents in the AD pipeline.
Symptomatic agents represent an important part of the AD drug-development pipeline. Improvement in cognitive and behavioral symptoms is a major goal of treatment and is achieved only partially by current therapies. There are 25 symptomatic cognitive enhancers or neuropsychiatric agents in the current pipeline comprising 27% of the entire drug-development pipeline. Symptomatic treatments are especially well represented in phase II where they comprise 33% of all agents at that stage of development. These agents enhance cholinergic signaling or capitalize on noncholinergic serotonergic, sigma-1, phosphodiesterase, or N-methyl-D-asparate (NMDA) mechanisms.
There is increasing recognition that combination therapies may be warranted to address the complex biology of AD [21] . Combinations have found success in other complex diseases such as cancer, tuberculosis, and human immunodeficiency virus infections. There are few examples in the AD pipeline of combination of agents in trials; ALZT-OP1a/1b is a combination approach at phase III, simvastatin/larginine/tetrahydrobiopterin is being assessed at phase II; and LY2599666 plus solanezumab is being tested in phase I. In addition to these pharmacodynamics combinations, AVP-786 is a pharmacokinetic combination of dextromethorphan and the CYP2D6 inhibitor, quinidine, used to elevate levels of dextromethorphan. Overall, combinations comprise a limited aspect of the AD drug-development pipeline and represent an important future direction of drug development.
Currently, DMTs spend relatively little time in phase II (average 49 weeks) and involve a small number of patients per trial arm (average 67). Given the 100% failure rate of DMTs in phase III, more thorough exploration of these agents in phase II may benefit drug-development programs and the likelihood of phase III success.
Biomarkers play an increasingly important role in AD drug development. The demonstration that approximately 25% of patients included in trials of clinical-diagnosed AD do not have elevated levels of brain amyloid when studied with amyloid imaging indicated that use of biomarkers was critical in identifying a population with the target pathology in trials of antiamyloid agents and that have an accurate diagnosis for inclusion of trials of other agents [13, 14] . Nearly, all current trials of antiamyloid agents require positive amyloid imaging at baseline to insure accurate diagnosis and include amyloid imaging as an outcome to determine the effect of the therapeutic intervention on the brain plaque burden. Target engagement biomarkers are now more commonly used in drug-development programs such as those for BACE inhibitors to show that a biological effect has been achieved and that clinical effects could reasonably be expected. CSF measurements of amyloid and tau, volumetric MRI, and amyloid PET are used approximately equally commonly in DMT programs; no consensus on a single biomarker or combination of biomarkers as Table 4 Percent of trials with specific biomarkers included (this calculation is based on the number of trials in which the inclusion of biomarkers is described) optimal to meet regulatory expectations for biomarker data has emerged. Of trials across all phases of AD drug development, 74% are completely or partially sponsored by the biopharmaceutical industry. Given the prominent role of industry in AD drug development, legislative incentives to attract the pharmaceutical and biotechnology industries to AD may be one of the means of enhancing the number of candidate agents entering the AD pipeline. Increased federal funding to augment the small number of trial sponsored by NIH (9% with total or partial NIH funding) might also enhance the pipeline. Funding for basic science through NIH or venture capital support of biotechnology companies is needed to identify new targets and generate new candidate therapies. Similarly, new strategies in drug development including more emphasis on demonstrating target engagement in early stage development and use of adaptive designs to support clinical trials decision making may accelerate the drug development process and decrease the number of latestage failures of agents in the pipeline.
This analysis is based on a review of clinicaltrials.gov and is subject to the limitations of that database. While inclusive of all trials in the United States and many non-US countries, it may not include all trials being conducted in other countries and the list of drugs we discuss may not be comprehensive from an international perspective. In addition, not all phase I trials are included on clinicaltrials.gov, especially when they are conducted in non-US phase I units, and we may underestimate the total number of agents being assessed in phase I. There is sometimes a lag in listing trials on clinicaltrials.gov, and the lists included here may not be fully comprehensive for the time window assessed. These limitations will affect some details of the analysis but not the overall view of the landscape of AD drug development.
In summary, the AD drug-development pipeline is modest in size and strikingly smaller than very active areas of experimental therapeutics such as cancer. The phase I candidate pool is particularly small and bodes poorly for a compelling set of agents to be advanced to phase II and III. Amyloid is the most common pharmaceutical target, reflecting the greater understanding of the pathophysiology of this peptide. Symptomatic agents are making progress toward treatment of both cognitive and behavioral symptoms of AD. Biomarkers are being integrated into DMT development programs. Every source of compounds including academic medical centers, NIH, philanthropic funders, biotechnology, and pharmaceutical companies should be attracted to AD drug development to create a larger pipeline and a greater chance of success of AD drug development.
